


RealRate

PHARMACEUTICAL 2021

Inozyme Pharma Inc. Rank 59 of 402







RealRate

Inozyme Pharma Inc. Rank 59 of 402

The relative strengths and weaknesses of Inozyme Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Inozyme Pharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 61% points. The greatest weakness of Inozyme Pharma Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 239%, being 191% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	150,979
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,973
Liabilities, Non-Current	0
Other Assets	15,736
Other Compr. Net Income	-3.0
Other Expenses	0
Other Liabilities	1,287
Other Net Income	617
Other Revenues	0
Property and Equipment	2,648
Research and Development	46,493
Selling, General and Administrative Expense	10,548

Output Variable	Value in 1000 USD
Assets	169,363
Liabilities	11,260
Expenses	57,041
Revenues	0
Stockholders Equity	158,103
Net Income	-56,424
Comprehensive Net Income	-56,426
Economic Capital Ratio	239%

